STOCK TITAN

Biogen Inc. - $BIIB STOCK NEWS

Welcome to our dedicated page for Biogen news (Ticker: $BIIB), a resource for investors and traders seeking the latest updates and insights on Biogen stock.

Biogen Inc. (Nasdaq: BIIB) is a pioneering biotechnology company founded in 1978, dedicated to discovering, developing, and delivering innovative therapies for people living with serious neurological and neurodegenerative diseases. With a robust portfolio of medicines, Biogen is a global leader in the treatment of multiple sclerosis (MS) and has introduced the first and only approved treatment for spinal muscular atrophy (SMA). The company is also at the forefront of research for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).

Headquartered in Cambridge, Massachusetts, Biogen operates worldwide with research facilities in Zug, Switzerland, and state-of-the-art manufacturing plants in North Carolina and Denmark. The company employs approximately 7,000 people globally, emphasizing a collaborative and inclusive work environment.

Biogen's significant achievements include the development of revolutionary MS treatments such as Avonex, Plegridy, Tysabri, Tecfidera, and Vumerity. The company also markets Spinraza for SMA and Leqembi for Alzheimer’s disease, in collaboration with partners like Ionis and Eisai respectively. Biogen continues to expand its pipeline with promising candidates currently in various stages of clinical trials.

Recent developments have seen Biogen and Eisai submit a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for monthly maintenance dosing of Leqembi, aimed at treating Alzheimer's disease in its early stages. Furthermore, Biogen published its 2023 Corporate Responsibility Report, highlighting its commitment to sustainable practices and social responsibility across four key pillars.

In addition to its core operations, Biogen collaborates with companies like Delta Flight Products to improve travel experiences for passengers with reduced mobility. This initiative reflects Biogen’s broader mission to enhance the quality of life for individuals facing debilitating conditions.

Biogen's financial health is robust, with strategic mergers and acquisitions like the recent purchase of Human Immunology Biosciences for $1.15 billion, aiming to bolster its immunology pipeline. The company’s comprehensive approach to business involves balancing bold scientific endeavors with prudent financial management to ensure long-term growth and shareholder value.

For more information about Biogen's latest news and updates, visit www.biogen.com.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none

FAQ

What does Biogen Inc. specialize in?

Biogen focuses on discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases.

Where is Biogen headquartered?

Biogen is headquartered in Cambridge, Massachusetts, with research operations in Zug, Switzerland.

What are some of Biogen's key products?

Key products include treatments for multiple sclerosis like Avonex, Tysabri, Tecfidera, and Vumerity, as well as Spinraza for spinal muscular atrophy and Leqembi for Alzheimer's disease.

How many employees does Biogen have?

Biogen employs approximately 7,000 people worldwide.

What recent acquisitions has Biogen made?

Biogen recently acquired Human Immunology Biosciences for $1.15 billion to expand its immunology pipeline.

What are Biogen’s latest research initiatives?

Biogen is researching treatments for Alzheimer’s, Parkinson’s, and ALS, with several drug candidates in phase 3 trials.

How is Biogen improving travel for people with mobility issues?

Biogen is collaborating with Delta Flight Products to develop solutions that enhance air travel for passengers with reduced mobility.

What is Biogen’s approach to corporate responsibility?

Biogen’s corporate responsibility strategy focuses on sustainable practices and social good, detailed in its 2023 Corporate Responsibility Report.

What is Leqembi and what is its significance?

Leqembi is a treatment for Alzheimer’s disease developed in collaboration with Eisai. It is currently under review by the FDA for monthly maintenance dosing.

Where can I find more information about Biogen?

More information is available on Biogen's official website at www.biogen.com.

Biogen Inc.

Nasdaq:BIIB

BIIB Rankings

BIIB Stock Data

32.61B
145.09M
0.16%
93.16%
2.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE